Background Cancers with a defective DNA mismatch repair (dMMR) system contain
thousands of mutations most frequently located in monomorphic microsatellites and are …

Background. Innovative drugs targeting the PD1/PD-L1 axis have opened promising
scenarios in modern cancer therapy. Plenty of assays and scoring systems have been …

Background Undifferentiated carcinoma with osteoclast-like giant cells (OGCs) of pancreas
(UCOGCP) is a rare subtype of pancreatic ductal adenocarcinoma (PDAC), which had …

Polyploid giant cancer cells (PGCC) constitute a dangerous subpopulation of cancer cells
and are a driving force in cancer recurrence. These unique cells arise from diploid tumor …

Objectives and background: Oral squamous cell carcinoma (OSCC) is a highly malignant
disease with an increasing incidence. The need to improve therapeutic strategies for …

The pathologist emerged in the personalized medicine era as a central actor in the definition
of the most adequate diagnostic and therapeutic algorithms. In the last decade …

To date, pancreatic cancer is still one of the most lethal cancers in the world, mainly due to
the lack of early diagnosis and personalized treatment strategies. In this context, the …

Immune-checkpoint inhibitors targeting the PD-1/PD-L1 axis have brought significant clinical
benefit in many solid cancer types, including gastrointestinal malignancies. However, it has …

Undifferentiated carcinoma of the pancreas is an aggressive but rare tumor for which several
other terms have been used to describe its histological appearance. In addition, as …

Pancreatic malignant exocrine tumors represent the most important cause of cancer-related
death for pancreatic neoplasms. The most common tumor type in this category is …